{
    "Trade/Device Name(s)": [
        "Elecsys FT4 IV"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K220456",
    "Predicate Device Reference 510(k) Number(s)": [
        "K131244"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEC"
    ],
    "Summary Letter Date": "April 7, 2023",
    "Summary Letter Received Date": "December 9, 2022",
    "Submission Date": "December 8, 2022",
    "Regulation Number(s)": [
        "21CFR862.1695"
    ],
    "Regulation Name(s)": [
        "Free Thyroxine Test System"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Free thyroxine (FT4)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Li-Heparin, K2-EDTA, K3-EDTA)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "cobas e immunoassay analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Competitive immunoassay"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys FT4 IV, an ECLIA-based immunoassay for quantitative determination of free thyroxine in serum and plasma on cobas e analyzers.",
    "Indications for Use Summary": "Quantitative in vitro determination of free thyroxine in human serum and plasma to aid in diagnosis and treatment of thyroid disease; intended for use with cobas e immunoassay analyzers.",
    "fda_folder": "Clinical Chemistry"
}